Adar Poonawalla, Serum Institute of India CEO (Dhiraj Singh/Bloomberg via Getty Images)

May 24, 2022 10:49 AM EDT

Covid-19 roundup: Serum Institute eyes Africa for global expansion — report; Junshi antiviral hits primary endpoint in late-stage trial

Paul Schloesser

Associate Editor

After Serum Institute CEO Adar Poonawalla announced last month that the world’s largest vaccine maker stopped producing doses of Covid-19 vaccines back in December …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Covid-19 roundup: Serum Institute eyes Africa for global expansion — report; Junshi antiviral hits primary endpoint in late-stage trial

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Covid-19 roundup: Serum In­sti­tute eyes Africa for glob­al ex­pan­sion — re­port; Jun­shi an­tivi­ral hits pri­ma­ry end­point in late-stage tri­al

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Covid-19 roundup: Serum Institute eyes Africa for global expansion — report; Junshi antiviral hits primary endpoint in late-stage trial

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?